Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease

Anticancer Research

Volumn 30, Issue 10, 2010, Pages 4357-4361

  Shukuya, Takehito ^a   Ishiwata, T ^a   Hara, M ^a   Muraki, K ^a   Shibayama, R ^a   Koyama, R ^a   Takahashi, K ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Carboplatin; Chemotherapy; Efficacy; Interstitial lung disease; Non small cell lung cancer; Paclitaxel; Safety

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HICCUP; HUMAN; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES;

EID: 78650235583     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Cancer Statistics in Japan 2009, http://ganjoho.ncc.go.jp/public/ statistics/backnumber/2009-en.html.
2. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y and Fukuoka M: Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18: 317-323, 2007.
3. Nicholson AG, Colby TV, Dubois RM, Hansell DM and Wells AU: The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 162: 2213-2217, 2000.
4. Raghu G, Nyberg F and Morgan G: The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer 91: S3-S10, 2004.
5. Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, Tsuboi M, Yokota S, Nakagawa K, Suga M, Japan Thoracic Radiology Group, Jiang H, Itoh Y, Armour A, Watkins C, Higenbottam T and Nyberg F: Interstitial lung disease in Japanese patients with lung cancer. A cohort and nested case-control study. Am J Respir Crit Care Med 177: 1348-1357, 2008.
6. Kim DS, Park JH, Park BK, Lee JS Nicholson AG and Colby T: Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 27: 143-150, 2006.
7. Hyzy R, Huang S, Myers J, Flaherty K and Martinez F: Acute exacerbation of idiopathic pulmonary fibrosis. Chest 132: 1652-1658, 2007.
8. Park IN, Kim DS, Shim TS, Lim CM, Lee SD, Koh Y, Kim WS, Kim WD, Jang SJ and Colby TV: Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest 132: 214-220, 2007.
9. Suda T, Kaida Y, Nakamura Y, Enomoto N, Fujisawa T, Imokawa S, Hashizume H, Naito T, Hashimoto D, Takehara Y, Inui N, Nakamura H, Colby TV and Chida K: Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir Med 103: 846-853, 2009.
10. Sakakibara T, Inoue A, Sugawara S, Maemondo M, Ishida T, Usui K, Abe T, Kanbe M, Watanabe H, Saijo Y and Nukiwa T: Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer. Ann Oncol 21: 795-799, 2010.
11. Socinski MA, Ivanova A, Bakri K, Wall J, Baggstrom MQ, Hensing TA, Mears A, Tynan M, Beaumont J, Peterman AH and Niell HB: A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Ann Oncol 17: 104-109, 2006.
12. Yasuda K, Igishi T, Kawasaki Y, Yamamoto M, Kato K, Matsumoto S, Kotani M, Sako T, Shigeoka Y, Sugitani A, Histuda Y and Shimizu E: Phase II trial of weekly paclitaxel in previously untreated advanced non-small cell lung cancer. Oncology 65: 224-228, 2003.